CJC-1295 DAC vs Sermorelin.

CJC-1295 with DAC (also written DAC:GRF, CJC-1295 DAC) is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). It is built on the bioactive N-terminal GHRH(1-29) fragment with several amino-acid substitutions, plus a "Drug Affinity Complex" (DAC): a maleimidopropionyl group that lets the peptide bind covalently to circulating albumin after injection. It was developed in the mid-2000s by ConjuChem Biotechnologies as an investigational drug; it is not an approved medicine and today circulates mainly as a research/gray-market peptide.

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH). This 1-29 fragment is the shortest portion of GHRH that retains full biological activity, so sermorelin behaves as a functional GHRH analog (a "secretagogue") rather than as growth hormone itself. It was marketed under the brand names Geref and Geref Diagnostic.

Like native GHRH, CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of growth hormone (GH), which in turn drives hepatic and peripheral IGF-1 production. Two engineering features extend its action: amino-acid substitutions in the GHRH(1-29) backbone resist cleavage by dipeptidyl-peptidase-4 (DPP-4), and the DAC maleimide group forms a covalent bond with cysteine-34 of serum albumin, shielding the peptide from renal filtration and proteolysis so it persists in plasma for days rather than minutes. Because it amplifies the body's own GH axis rather than supplying exogenous GH, secretion remains somewhat pulsatile and subject to negative feedback (e.g., somatostatin).

Sermorelin binds the GHRH receptor on pituitary somatotroph cells, a Gs-protein-coupled receptor, raising intracellular cAMP and stimulating synthesis and pulsatile secretion of endogenous growth hormone. Because it acts upstream on the pituitary rather than supplying exogenous GH, its effect is gated by an intact pituitary and remains subject to normal physiological brakes, most importantly negative feedback from somatostatin and from GH/IGF-1. Downstream, any GH released drives hepatic production of insulin-like growth factor 1 (IGF-1). This "releaser" mechanism is the basis for the long-standing claim that sermorelin produces a more physiologic, pulsatile GH profile than direct recombinant GH injection, though that pharmacodynamic difference has not been shown to translate into superior clinical outcomes.

Human evidence comes mainly from early-phase ConjuChem trials in healthy adults. Teichman et al. (JCEM, 2006) reported that single subcutaneous doses produced dose-dependent, sustained elevations of GH and IGF-1, with IGF-1 remaining above baseline for several days and repeated weekly/biweekly dosing maintaining elevated IGF-1. Ionescu and Frohman (JCEM, 2006) showed that despite continuous GHRH-receptor stimulation, GH secretion remained pulsatile in healthy men. Preclinical support includes Alba et al. (Am J Physiol Endocrinol Metab, 2006), where once-daily CJC-1295 normalized growth in GHRH-knockout mice, and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), which characterized GH/IGF-1-axis-driven serum protein changes. Crucially, there are no published controlled trials demonstrating clinical outcomes (body composition, strength, fat loss, anti-aging, or healing) in humans; the human data establish a pharmacodynamic GH/IGF-1 effect, not proven therapeutic benefit, and the program was discontinued without an approved indication.

The strongest human evidence is in pediatric diagnostics and idiopathic GH deficiency: sermorelin was studied and FDA-approved both as a provocative test of pituitary GH reserve and for treating growth failure in children with GHRH-responsive (hypothalamic) GH deficiency, where it can increase growth velocity (reviewed in BioDrugs 1999, PMID 18031173). Evidence for the popular adult "anti-aging," body-composition, sleep, and recovery claims is largely mechanistic or extrapolated rather than demonstrated; a frequently cited Clinical Interventions in Aging review (PMID 18046908) frames sermorelin in adult GH insufficiency as a rational but largely hypothetical approach, not an outcome-proven therapy. Notably, the well-known randomized controlled trial showing cognitive benefit from a GHRH analog in older adults and mild cognitive impairment (Baker et al., Archives of Neurology 2012, PMID 22869065) used tesamorelin, a different stabilized GHRH(1-44) analog, not sermorelin, so it should not be cited as direct sermorelin evidence. Overall, robust randomized trials of sermorelin for adult quality-of-life, longevity, or athletic outcomes are essentially absent.

In the short early-phase human studies, the most consistently noted effects were injection-site reactions and transient flushing; sustained IGF-1 elevation also raises theoretical concerns common to GH-axis stimulation, such as fluid retention, joint discomfort, carpal-tunnel-type symptoms, and reduced insulin sensitivity. Long-term human safety is essentially uncharacterized: no large or long-duration controlled trials were completed, and chronically elevated GH/IGF-1 is a biologically plausible (though unproven for this compound) concern for promoting growth of existing neoplasms. Real-world risk is compounded by the fact that material sold as "CJC-1295 DAC" is unregulated and may vary in purity, identity, or sterility. No dosing or administration guidance is provided here.

In its approved pediatric and diagnostic use, sermorelin was generally well tolerated, with the most common reactions being transient injection-site reactions (redness, swelling, pain) and, less often, flushing, headache, dizziness, or transient warmth; uncommon hypersensitivity reactions were reported. Because it raises GH and IGF-1, the theoretical class concerns that apply to GH-axis stimulation are relevant, including fluid retention, joint or muscle discomfort, insulin resistance/glucose changes, and the general caution around GH-axis stimulation in people with active malignancy. Most safety data come from short-term, monitored, mostly pediatric settings; long-term safety of chronic adult use, especially via compounded products sold for off-label "wellness" purposes, has not been established, and compounded preparations carry additional uncertainty around purity, sterility, and dose accuracy. No doses or regimens are provided here.

CJC-1295 (with or without DAC) is not approved by the FDA or any major regulator for any use; clinical development was discontinued and it is treated as an unapproved/investigational substance, with U.S. authorities also flagging it as unsuitable for pharmacy compounding. It is prohibited in sport at all times by the World Anti-Doping Agency as a GH-releasing factor under Category S2 of the Prohibited List.

Sermorelin acetate was FDA-approved (brand Geref / Geref Diagnostic) for diagnostic testing of pituitary GH reserve and for idiopathic GH deficiency in children, but the branded products were voluntarily withdrawn from the US market in 2008 for commercial reasons (not for safety or efficacy failures); it is currently available in the US only as a compounded preparation, with no FDA-approved finished-drug product on the market.